Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Intermediate AMD: If you have intermediate AMD in one or both eyes, AREDS 2 supplements may help prevent it from turning into late-stage AMD, which causes significant vision loss. Late AMD in One Eye: ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach from USD 10.77 billion in 2025 to USD 18.59 Billion by 2033, growing at a ...

In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

HDL cholesterol levels demonstrate a U-shaped association with AMD, in which both high and low levels elevate risk.